Lupus nephritis-related chronic kidney disease

J Lichtnekert, HJ Anders - Nature Reviews Rheumatology, 2024 - nature.com
Lupus nephritis is a common complication of systemic lupus erythematosus (SLE) and a
determinant of overall morbidity and mortality, as lupus nephritis-related chronic kidney …

Drug repurposing for glomerular diseases: an underutilized resource

MSY Ng, G Kaur, RS Francis, CM Hawley… - Nature Reviews …, 2024 - nature.com
Drug repurposing in glomerular disease can deliver opportunities for steroid-free regimens,
enable personalized multi-target options for resistant or relapsing disease and enhance …

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

EM Apperloo, JL Gorriz, MJ Soler, S Cigarrán Guldris… - Nature Medicine, 2024 - nature.com
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with
type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo …

Therapy of IgA nephropathy: time for a paradigm change

J Barratt, RA Lafayette, J Floege - Frontiers in Medicine, 2024 - frontiersin.org
Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients
reaching kidney failure within their lifetime. Therefore, the primary goal for the treatment of …

Endothelin system in hypertension and chronic kidney disease

EL Schiffrin, DM Pollock - Hypertension, 2024 - Am Heart Assoc
ET (endothelin) is a powerful vasoconstrictor 21-amino acid peptide present in many tissues,
which exerts many physiological functions across the body and participates as a mediator in …

The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial

HJL Heerspink, X Du, Y Xu, Y Zhang… - Journal of the …, 2024 - journals.lww.com
Background Endothelin receptor type A activation contributes to kidney injury in patients with
IgA nephropathy. SC0062 is a novel selective endothelin receptor type A antagonist. We …

Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial

A Morrow, R Young, GR Abraham, S Hoole… - Circulation, 2024 - ahajournals.org
BACKGROUND: Microvascular angina is associated with dysregulation of the endothelin
system and impairments in myocardial blood flow, exercise capacity, and health-related …

The major global burden of chronic kidney disease

M Jadoul, M Aoun, MM Imani - The Lancet Global Health, 2024 - thelancet.com
Chronic kidney disease is a global public health problem, involving about 10% of the global
population. 1 The awareness of this major burden is relatively recent and still incomplete …

Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection

A Mazzieri, F Porcellati, F Timio, G Reboldi - International Journal of …, 2024 - mdpi.com
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …

[HTML][HTML] Endothelin Inhibitors in Chronic Kidney Disease: New Treatment Prospects

A Rakotoarison, M Kepinska, A Konieczny… - Journal of Clinical …, 2024 - mdpi.com
The endothelin system is reported to play a significant role in glomerular and
tubulointerstitial kidney disease. In the kidney, endothelins are produced in mesangial cells …